All Resources

Canadian publicly funded prescription drug plans, expenditures and an overview of patient impacts

Description

This report compares publicly-funded drug programs across Canada and determines where Alberta fits in comparison to the other provinces/territories with respect to its publicly-funded drug plans,... More ≫

Description

This report compares publicly-funded drug programs across Canada and determines where Alberta fits in comparison to the other provinces/territories with respect to its publicly-funded drug plans, drug access, expenditures, and patient-borne out-of-pocket costs.

Tags

Prescription drug misuse in Alberta : everyone’s problem

Description

The misuse and abuse of prescription drugs is harming too many Albertans. Ease of access and affordability of medications such as opioid pain relievers, stimulants, tranquillizers and sedatives,... More ≫

Description

The misuse and abuse of prescription drugs is harming too many Albertans. Ease of access and affordability of medications such as opioid pain relievers, stimulants, tranquillizers and sedatives, can quickly and easily lead to addiction. Compounding this ease of accessibility and affordability is the false perception that if a health care practitioner prescribes these medications, they are safe. This report from the Office of the Chief Medical Officer of Health provides statistics on the prevalence of prescription drug use and misuse, outlines the main issues that need to be addressed, and provides four recommended actions to address the problem.

Tags

Alberta pharmaceutical strategy : stakeholder consultation

Description

A Health Action Plan for Alberta was announced by the Minister of Health and Wellness in April 2008. A key component of this plan is the development of a pharmaceutical strategy. A consultation... More ≫

Description

A Health Action Plan for Alberta was announced by the Minister of Health and Wellness in April 2008. A key component of this plan is the development of a pharmaceutical strategy. A consultation process was implemented to meet key stakeholders, summarize their comments, and make key recommendations. Meetings were held with 16 stakeholder groups representing patients, physicians, pharmacists, employers, benefit providers, and the pharmaceutical industry. Written submissions were also welcomed. This document summarizes the stakeholders input and presents 10 recommendations for the government to implement.

Tags